SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DrGamble who wrote (67)12/9/1998 5:56:00 PM
From: whyretire  Read Replies (1) of 1084
 
It sounds like a good thing. It could be great, but the findings
reported here (although promising) are only preliminary -- 10
patients. Further, only 4/10 patients had a successful result.
this is not overwhelming. They claim that these patients were sick,
and none should have survived, but this is true of all BMT patients.
Was there a control group of equally sick patients who received
conventional treatment? I didn't see one. This may be no better than
regular BMT. Why did the others fail? Was it graft vs. host disease?
(rejection of the new marrow). How does this compare, again
with regular BMT? Hackensack U is not really one of the top 10 in
medical research.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News